Matches in SemOpenAlex for { <https://semopenalex.org/work/W4312996838> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4312996838 endingPage "234" @default.
- W4312996838 startingPage "222" @default.
- W4312996838 abstract "The present study investigate the effects of oral administration of ayurvedic nanoparticle drug Rasamanikya against ESBL producing gastrointestinal gram-negative bacteria Escherichia coli in experimental broiler chicken and haemato-biochemical, pathological alteration due to drug administration. At the age of 21 days, the birds were divided into three groups i.e. group-C served as control group, group-E treated with Enrofloxacin which act as standard control group and group-RM treated with test drug Rasamanikya, containing six birds in each group. On the day 22, the experiment (Drug trial) was started and continued for next 28 days. On the day 0, 7, 14, 21 and 28 of experiment fecal sample was collected by using fecal swab from each bird of three groups to examine the ESBL producing gastrointestinal gram-negative bacterial count. Blood sample also be collected on day 0, 7, 14 and 28 of experiment from wing vein with the help of tuberculin syringe in sterile vial under aseptic condition to evaluate the haemato-biochemical parameters i.e. Hb%, SGPT, SGOT, ALP, Urea and Creatinine. After 28 days of experiment, at the age of 50th day, the birds were slaughtered to collect tissue sample from heart, lung, liver and kidney. Illeo-caecal junction tissue was also collected to examine the illeo-caecal coliform count. Fecal coliform count decreased significantly in RM treated group in comparison to control group. There was no significant (P< 0.01) alteration in hemoglobin percentage, uric acid and creatinine level but serum SGPT, SGOT and ALP increased significantly in RM treated group. The illeo-caecal coliform count was decreased significantly in standard control and Rasa Manikya treated groups in both dilutions 1:50 and 1:100 in comparison to normal control group. The result indicate that the test drug Rasamanikya able to decrease the fecal and illeo-caecal coliform count but histopathological findings clearly showed the drug causes chronic toxicity in birds of RM treated group." @default.
- W4312996838 created "2023-01-05" @default.
- W4312996838 creator A5001679789 @default.
- W4312996838 creator A5012157028 @default.
- W4312996838 creator A5013143957 @default.
- W4312996838 creator A5034247573 @default.
- W4312996838 creator A5042766981 @default.
- W4312996838 creator A5043222188 @default.
- W4312996838 creator A5069402702 @default.
- W4312996838 date "2022-09-10" @default.
- W4312996838 modified "2023-10-14" @default.
- W4312996838 title "Evaluation of Ayurvedic Nanoparticle Drug Rasamanikya against ESBL Producing Gastrointestinal Gram-negative Bacteria Escherichia coli in Experimental Poultry" @default.
- W4312996838 doi "https://doi.org/10.20546/ijcmas.2022.1109.025" @default.
- W4312996838 hasPublicationYear "2022" @default.
- W4312996838 type Work @default.
- W4312996838 citedByCount "0" @default.
- W4312996838 crossrefType "journal-article" @default.
- W4312996838 hasAuthorship W4312996838A5001679789 @default.
- W4312996838 hasAuthorship W4312996838A5012157028 @default.
- W4312996838 hasAuthorship W4312996838A5013143957 @default.
- W4312996838 hasAuthorship W4312996838A5034247573 @default.
- W4312996838 hasAuthorship W4312996838A5042766981 @default.
- W4312996838 hasAuthorship W4312996838A5043222188 @default.
- W4312996838 hasAuthorship W4312996838A5069402702 @default.
- W4312996838 hasBestOaLocation W43129968381 @default.
- W4312996838 hasConcept C126322002 @default.
- W4312996838 hasConcept C140793950 @default.
- W4312996838 hasConcept C147789679 @default.
- W4312996838 hasConcept C185592680 @default.
- W4312996838 hasConcept C2778512257 @default.
- W4312996838 hasConcept C2779906673 @default.
- W4312996838 hasConcept C2780289900 @default.
- W4312996838 hasConcept C2780306776 @default.
- W4312996838 hasConcept C42972112 @default.
- W4312996838 hasConcept C501593827 @default.
- W4312996838 hasConcept C61716771 @default.
- W4312996838 hasConcept C71924100 @default.
- W4312996838 hasConcept C72092618 @default.
- W4312996838 hasConcept C86803240 @default.
- W4312996838 hasConcept C89423630 @default.
- W4312996838 hasConceptScore W4312996838C126322002 @default.
- W4312996838 hasConceptScore W4312996838C140793950 @default.
- W4312996838 hasConceptScore W4312996838C147789679 @default.
- W4312996838 hasConceptScore W4312996838C185592680 @default.
- W4312996838 hasConceptScore W4312996838C2778512257 @default.
- W4312996838 hasConceptScore W4312996838C2779906673 @default.
- W4312996838 hasConceptScore W4312996838C2780289900 @default.
- W4312996838 hasConceptScore W4312996838C2780306776 @default.
- W4312996838 hasConceptScore W4312996838C42972112 @default.
- W4312996838 hasConceptScore W4312996838C501593827 @default.
- W4312996838 hasConceptScore W4312996838C61716771 @default.
- W4312996838 hasConceptScore W4312996838C71924100 @default.
- W4312996838 hasConceptScore W4312996838C72092618 @default.
- W4312996838 hasConceptScore W4312996838C86803240 @default.
- W4312996838 hasConceptScore W4312996838C89423630 @default.
- W4312996838 hasIssue "9" @default.
- W4312996838 hasLocation W43129968381 @default.
- W4312996838 hasOpenAccess W4312996838 @default.
- W4312996838 hasPrimaryLocation W43129968381 @default.
- W4312996838 hasRelatedWork W1227599330 @default.
- W4312996838 hasRelatedWork W138542293 @default.
- W4312996838 hasRelatedWork W1577746088 @default.
- W4312996838 hasRelatedWork W2043072843 @default.
- W4312996838 hasRelatedWork W2047222414 @default.
- W4312996838 hasRelatedWork W2141879584 @default.
- W4312996838 hasRelatedWork W2351204207 @default.
- W4312996838 hasRelatedWork W2391545707 @default.
- W4312996838 hasRelatedWork W2977366781 @default.
- W4312996838 hasRelatedWork W4360929226 @default.
- W4312996838 hasVolume "11" @default.
- W4312996838 isParatext "false" @default.
- W4312996838 isRetracted "false" @default.
- W4312996838 workType "article" @default.